UCB

What UCB does

UCB S.A. is a global biopharmaceutical company headquartered in Brussels, Belgium, with U.S. operations anchored in Smyrna, Georgia. Founded in 1923 (originally as Union Chimique Belge), UCB employs more than 9,000 people across approximately 40 countries and operates as a publicly listed entity on Euronext Brussels (ticker: UCB). The company focuses on severe diseases of the immune system and central nervous system, with therapeutic franchises in immunology (BIMZELX/bimekizumab, CIMZIA/certolizumab pegol), neurology and rare epilepsy (FINTEPLA/fenfluramine for Dravet syndrome and Lennox-Gastaut syndrome), myasthenia gravis (RYSTIGGO/rozanolixizumab and ZILBRYSQ/zilucoplan), and ultra-rare mitochondrial disease (KYGEVVI/doxecitine and doxribtimine for TK2d). FY2025 revenue was €7.7 billion, with BIMZELX alone contributing €2.22 billion in blockbuster sales.

The company's underlying technology platforms span dual cytokine inhibition (IL-17A/IL-17F), regenerative pluripotent stem cell therapy (NRTX-1001 acquired via Neurona Therapeutics), and T-cell engager bispecific antibodies (BCMAxCD3 cizutamig via Candid Therapeutics, CD19/CD3 ATG-201 via Antengene license). UCB invests in AI-enabled drug discovery through a multi-year collaboration with Microsoft, particularly for its Targeted Protein Degradation program. The company generates revenue primarily through direct sales of proprietary pharmaceutical products via enterprise field sales teams, medical science liaisons, and specialty pharmacy distribution (including PANTHERx Rare as exclusive distributor for KYGEVVI). UCB completed three major transactions in 2026 alone (Candid Therapeutics for up to $2.2B, Neurona Therapeutics for up to $1.15B, Antengene licensing with up to $1.1B+ in milestones) and is investing $2 billion in a new U.S. biologics manufacturing campus in Gwinnett County, Georgia, signaling an aggressive expansion of both pipeline depth and U.S. production capacity.

Name

UCB

Legal name

UCB, Inc.

Website

https://ucb-usa.com

Company type

Public

Founded year

1923

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

UCB is a global biopharmaceutical company developing specialty medicines for severe immune-mediated and central nervous system diseases, including immunology, epilepsy, myasthenia gravis, and rare mitochondrial disorders, generating €7.7B in 2025 revenue with blockbuster drug BIMZELX.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Bispecific & Multispecific Antibodies (HLAAAAAF), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Biopharmaceutical medicines
• Immunology therapeutics
• Neurology treatments
• Rare disease therapies
• Monoclonal antibody drugs

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Infrastructure, Marketing or Sales, Personnel, Supply Chain, Operations

Revenue model

1. Pharmaceutical Product Sales: UCB generates revenue primarily through sales of proprietary pharmaceutical products. Key products include BIMZELX (bimekizumab) for immunology/dermatology, FINTEPLA (fenfluramine) for epilepsy, RYSTIGGO and ZILBRYSQ for myasthenia gravis, and KYGEVVI for rare mitochondrial disease. Revenue is generated through direct sales to healthcare providers and specialty pharmacy distribution.
2. Blockbuster Drug Revenue - BIMZELX: BIMZELX has become a blockbuster drug with €2.22 billion in 2025 sales, expected to reach at least €4 billion. The drug is approved for multiple indications including plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.
3. Licensing and Milestone Payments: UCB generates revenue through licensing agreements including upfront payments and milestone payments. Examples include $80 million upfront from Antengene for ATG-201 licensing, plus potential $1.1 billion in development and commercial milestones.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

UCB develops, manufactures, and commercializes specialty biopharmaceutical medicines for severe diseases of the immune system and central nervous system. Core marketed products include BIMZELX (bimekizumab) for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; FINTEPLA (fenfluramine) for Dravet syndrome and Lennox-Gastaut syndrome; RYSTIGGO and ZILBRYSQ for generalized myasthenia gravis; KYGEVVI for thymidine kinase 2 deficiency; and CIMZIA for inflammatory conditions. The company invests in monoclonal antibodies, regenerative cell therapies, and T-cell engager platforms.

Differentiator

Problem solved

Functional benefit

Brands

• BIMZELX (bimekizumab): Monoclonal antibody treatment for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa
• FINTEPLA (fenfluramine)
• RYSTIGGO (rozanolixizumab)
• ZILBRYSQ (zilucoplan)
• KYGEVVI (doxecitine and doxribtimine)
• CIMZIA (certolizumab pegol)

Products and services

• BIMZELX (bimekizumab) Humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F cytokines; used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa in adult patients.
• FINTEPLA (fenfluramine) Treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients of all ages; administered under a REMS program for safety.
• RYSTIGGO (rozanolixizumab-noli) Treatment for generalized myasthenia gravis (gMG) in adult patients who are anti-AChR or anti-MuSK antibody positive.
• ZILBRYSQ (zilucoplan) Treatment for generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive; available as pre-filled syringe and pre-filled pen.
• KYGEVVI (doxecitine and doxribtimine) First FDA-approved treatment for thymidine kinase 2 deficiency (TK2d), a rare mitochondrial disease affecting muscle and respiratory functions.
• CIMZIA (certolizumab pegol) Treatment for various inflammatory conditions including rheumatoid arthritis, Crohn's disease, and psoriasis.

Quantifiable outcome

• 49.1% of BIMZELX patients achieved ACR50 primary endpoint vs 38.4% for risankizumab (p=0.0078) in psoriatic arthritis
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Candid TherapeuticscoreStrategic or Co-development Partner · 3 May 2026UCB signed definitive agreement to acquire Candid Therapeutics for up to $2.2 billion ($2B upfront plus up to $200M milestones). Candid is a privately held clinical-stage biotech developing T-cell engagers for autoimmune diseases. Lead asset cizutamig is a BCMAxCD3 bispecific antibody being evaluated across 10+ autoimmune indications in over 100 patients.
• Myasthenia Gravis Foundation of AmericaminorGTM or Marketing Partner · 20 April 2026UCB partnered with MGFA and Factor Meals to launch MGFA Food Support Program, providing premade meals to 250 MG families living in nutrition deserts or facing food insecurity. UCB markets Rystiggo and Zilbrysq for MG patients.
• Neurona TherapeuticscoreStrategic or Co-development Partner · 17 April 2026UCB acquiring Neurona Therapeutics for up to $1.15 billion ($650M upfront plus up to $500M milestones). Neurona is developing NRTX-1001, a neuronal cell therapy for drug-resistant mesial temporal lobe epilepsy currently in Phase I/II trials with FDA RMAT and EMA PRIME designations.
• Gwinnett County, GeorgiaminorOthers · 25 March 2026Gwinnett County committed $174 million in incentives and infrastructure investments to support UCB's $2 billion biologics manufacturing facility. Project represents largest capital investment in Gwinnett County history.
• PANTHERx RarecoreChannel Partner/ Reseller/ Distributor · 23 March 2026PANTHERx Rare selected as exclusive specialty pharmacy for distribution of KYGEVVI (doxecitine and doxribtimine) for TK2d, a rare mitochondrial disease. PANTHERx will support patients through its RxARECARE model.
• AntengenecoreStrategic or Co-development Partner · 4 March 2026Global licensing deal where Antengene granted UCB worldwide exclusive rights to develop, manufacture, and commercialize ATG-201 (CD19/CD3 bispecific TCE for autoimmune diseases). UCB paying $80M upfront with potential for $1.1B+ in development and commercial milestones plus royalties.
• MicrosoftcoreTechnology or Integration · 22 February 2022Expanded multi-year strategic collaboration combining Microsoft's computational services, cloud, and AI with UCB's drug discovery and development capabilities. First use case is AI-enabled workflows for Targeted Protein Degradation platform.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• AbbVie: Global biopharmaceutical leader with a deep immunology portfolio (Humira, Skyrizi, Rinvoq) overlapping directly with UCB's immunology franchise. Both compete in psoriasis, psoriatic arthritis, and adjacent autoimmune indications, and AbbVie's Skyrizi is the benchmark head-to-head competitor for BIMZELX.
• Novartis: Major biopharmaceutical player with Cosentyx (IL-17A inhibitor) as a direct BIMZELX competitor in psoriasis and rheumatology. Novartis also has neurology and rare disease assets, paralleling UCB's diversified specialty pharma footprint.
• Eli Lilly: Operates Taltz (IL-17A inhibitor) competing head-to-head with BIMZELX in psoriasis and rheumatology. Lilly's immunology franchise and growing biologics pipeline position it as a key large-cap competitor in UCB's core indications.
• Sanofi: Global biopharma with Dupixent (IL-4/13) dominating immunology adjacencies and an expanding rare disease/neurology footprint (e.g., rare disease acquisitions). Comparable in scale and therapeutic breadth to UCB, especially across specialty and rare indications.
• GSK: Specialty biopharma with Benlysta in autoimmune disease and a growing rare disease and immunology pipeline. Comparable in therapeutic-area focus (specialty immunology + rare disease) and global commercial scale to UCB.
• Bristol-Myers Squibb: Major biopharma with immunology (e.g., Zeposia, Sotyktu) competing in psoriasis and autoimmune disease alongside UCB. BMS's recent emphasis on T-cell engagers (multiple myeloma) parallels UCB's Candid-driven move into TCEs for autoimmune indications.

Direct peers

• Biogen: Neurology-focused biopharma with overlap in epilepsy and rare neurological disease adjacencies. Both companies pursue innovative CNS mechanisms, making Biogen a relevant direct peer in UCB's neurology and rare epilepsies franchise.
• Jazz Pharmaceuticals: Specialty biopharma with Epidiolex (cannabidiol) competing in Dravet, LGS, and tuberous sclerosis epilepsies — directly adjacent to UCB's FINTEPLA franchise. Similar size, rare neurology focus, and channel-based distribution model.
• Lundbeck: CNS-focused specialty biopharma with deep epilepsy and neurology heritage. Comparable mid-cap specialty profile to UCB's neurology franchise, with similar reliance on a small number of differentiated CNS assets.

Emerging players

• Regeneron: Antibody-driven biopharma with Dupixent (with Sanofi) and an immunology/immunology-adjacent pipeline. Comparable technology profile to UCB's monoclonal antibody discovery efforts and overlapping therapeutic-area focus in inflammatory disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/UCBUSA
• YouTubeyoutube.com/channel/UCE3zRh_3Ukv2MfbiSTZe_-g/featured
• Facebookfacebook.com/UCBBiopharma
• LinkedInlinkedin.com/company/ucb-pharma
• Instagraminstagram.com/ucb_usa

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UCB